Streetbeat News

Regulatory

BTC-USD

DOGE-USD

ETH-USD

Major cryptocurrencies including Bitcoin, Ethereum, and Dogecoin experienced declines, with significant liquidations occurring in the past 24 hours. The global cryptocurrency market cap decreased by 2.03%. Meanwhile, the Nasdaq Composite fell, while the Dow Jones and S&P 500 saw slight gains. Federal Reserve minutes indicated no imminent rate cuts. Analysts predict a correction for Bitcoin before a potential rise, noting mixed behavior among crypto whales but a trend of accumulation among the largest holders.

Portfolio Pulse from Mehab Qureshi

February 22, 2024 | 2:52 am

NPSCY

X

A Reuters poll indicates nearly half of Japanese companies view a potential Trump presidency as a business risk, primarily due to concerns over protectionist policies. The apprehension stems from Trump's stance on blocking the acquisition of United States Steel Corporation (NYSE:X) by Nippon Steel Corporation (OTC:NPSCY), which could impact future acquisitions and shareholder interests in U.S. Steel.

Portfolio Pulse from Benzinga Neuro

February 22, 2024 | 2:06 am

AAPL

Apple Inc. has announced a significant security upgrade for iMessage, introducing a new cryptographic protocol named PQ3 to combat potential quantum computing threats. This overhaul aims to prepare for the advent of quantum computing, which could compromise current encryption methods. The upgrade is part of Apple's efforts to maintain cutting-edge security, amidst concerns over quantum computing's ability to break conventional encryption. Additionally, recent developments include the EU's dismissal of antitrust threats against iMessage and speculation about Chinese government influence on Apple's decision to support RCS in iMessage by 2024.

Portfolio Pulse from Ananya Gairola

February 22, 2024 | 1:35 am

UAN

CVR Partners, LP (NYSE:UAN), a producer of ammonia and urea ammonium nitrate fertilizer products, has filed its Form 10-K annual report for the fiscal year ended December 31, 2023. The report is available on the CVR Partners website and unitholders can request a hard copy for free.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 10:37 pm

FLJ

FLJ Group Limited has received a deficiency notice from NASDAQ, indicating that it has failed to meet the minimum listing requirements. This could potentially lead to delisting if the issues are not resolved.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 10:27 pm

PTGX

Protagonist Therapeutics announced the publication of results from its Phase 2 REVIVE trial of Rusfertide in treating Polycythemia Vera, a type of blood cancer. The trial's outcomes could influence the company's future development strategies and market positioning.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 10:27 pm

NVDA

Nvidia has disclosed in an SEC filing that its new 'Notice of Advanced Computing' process with U.S. regulators has not led to approvals for exporting controlled chips to China. This development could impact Nvidia's ability to sell its products in one of its key markets.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 10:18 pm

NVDA

Nvidia has begun shipping alternative products to the China market in limited quantities, according to a recent SEC filing. However, the company has not yet received licenses to ship its restricted chips, including the A800 and H800 models, to China. This development comes amidst increasing regulatory scrutiny and trade tensions between the US and China, potentially affecting Nvidia's business operations and revenue in one of its largest markets.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 10:16 pm

NVDA

Nvidia has received requests for information from antitrust regulators in France, the European Union, the United Kingdom, and China regarding its GPU sales and supply allocation efforts. This development could indicate regulatory scrutiny over Nvidia's business practices in these regions.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 10:09 pm

CLPT

ClearPoint Neuro, Inc. (NASDAQ:CLPT) announced FDA clearance and first-in-human cases for its ClearPoint 2.2 Software with integrated Maestro Brain Modeling. Additionally, a validation study for the ClearPoint Maestro Brain Model was published in NeuroImage. The ClearPoint system offers precise navigation for various brain procedures, with the Maestro Brain Model enhancing accuracy and reproducibility in segmentation of brain structures. The first clinical cases using ClearPoint 2.2 were successfully completed, with a full market release expected in the second half of the year.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 9:54 pm